Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Ir J Med Sci ; 192(3): 1517-1523, 2023 Jun.
Article in English | MEDLINE | ID: mdl-35854192

ABSTRACT

BACKGROUND: Contradictory opinions exist regarding the use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with hypertension, which is the most common comorbidity associated with COVID-19. Herein, the effects of ACEIs and ARBs on outcomes of COVID-19 patients were evaluated. METHODS: In this cross-sectional study, the outcomes of COVID-19 patients were compared between patients who received pretreatment ACEIs or ARBs and those who did not. RESULTS: The incidence of moderate and severe forms of COVID-19 was significantly higher in patients taking ACEI/ARB drugs (P-value = 0.012). Also, patients taking ACEI/ARB drugs (P-value = 0.034), patients with hypertension (P-value = 0.011), and patients with dyslipidemia (P-value = 0.011) experienced more severe forms of COVID-19. There was an association between increased length of hospital stay and dyslipidemia (P-value = 0.033) and the use of ACEI/ARB drugs (P-value = 0.041), while no correlation was found between other parameters in univariate linear regression analysis as well as multivariate linear regression. There was an association between increased mortality of patients with increasing age (P-value < 0.001), BMI greater than 30 kg/m2 (P-value = 0.02), asthma (P-value = 0.003), and dyslipidemia (P-value = 0.045). CONCLUSIONS: ACEI/ARB drugs put COVID-19 patients at high risk for moderate to severe forms of COVID-19 and higher length of hospital stay. Although, it is notable that these drugs did not significantly affect specific adverse outcomes of COVID-19, such as the need for admission to the intensive care unit (ICU), length of ICU stay, ventilation, and mortality.


Subject(s)
COVID-19 , Hypertension , Humans , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , COVID-19/complications , Angiotensin Receptor Antagonists/therapeutic use , Cross-Sectional Studies , SARS-CoV-2 , Retrospective Studies , Hypertension/drug therapy , Hypertension/epidemiology
2.
Front Cell Infect Microbiol ; 12: 1103226, 2022.
Article in English | MEDLINE | ID: mdl-36619762

ABSTRACT

Introduction: The occurrence of oral candidiasis (OC) is expected in patients with COVID-19, especially those with moderate to severe forms of infection who are hospitalized and may be on long-term use of broad-spectrum antibiotics or prolonged corticosteroid therapy. We aimed to characterize clinical conditions, the prevalence profile of Candida species, and outcomes of COVID-19 patients with OC. Methods: In this observational study, oral samples were obtained from COVID-19 patients suspected of OC admitted to Razi teaching hospital. Patients with OC were monitored daily until discharge from the hospital. Species identification was performed by a two-step multiplex assay named YEAST PLEX, which identifies 17 clinically important uncommon to common yeast strains. Results: Among the 4133 patients admitted with COVID-19, 120 (2.90%) suffered from OC. The onset of signs and symptoms of OC in patients was, on average (2.92 ± 3.596 days) with a range (of 1-29 days). The most common OC presentation was white or yellow macules on the buccal surface or the tongue. In (39.16%) of patients suffering from OC multiple Candida strains (with two or more Candida spp.) were identified. The most common Candida species were C. albicans (60.57%), followed by C. glabrata (17.14%), C. tropicalis (11.42%), C. kefyr (10.83%) and C. krusei (3.42%). Notably, OC caused by multiple Candida strains was more predominant in patients under corticosteroid therapy (P <0.0001), broad-spectrum antibiotics therapy (P = 0.028), and those who used nasal corticosteroid spray (P <0.0001). The majority of patients who recovered from OC at the time of discharge were patients with OC by single Candida species (P = 0.049). Discussion: Use of corticosteroids and antimicrobial therapy in COVID-19 patients increases risk of OC by multiple Candida strains.


Subject(s)
COVID-19 , Candidiasis, Oral , Communicable Diseases , Humans , Candida , Candidiasis, Oral/drug therapy , Candidiasis, Oral/epidemiology , Candida albicans , Candida glabrata , Candida tropicalis , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/therapeutic use
3.
BMC Infect Dis ; 21(1): 450, 2021 May 18.
Article in English | MEDLINE | ID: mdl-34006228

ABSTRACT

BACKGROUND: A protective effect of vitamin D against COVID-19 infection is under investigation. We aimed to analyze the effect of vitamin D sufficiency on the clinical outcomes of patients infected with COVID-19. METHODS: In this cross-sectional study we analyzed the vitamin D levels of COVID-19 patients who were admitted to Razi Hospital (an infectious disease referral center in Mazandaran province in northern Iran) from February to March 2020. Overall, a cutoff point of 30 ng/mL was used for the definition of vitamin D sufficiency. RESULTS: One hundred fifty-three patients were analyzed in this study who had laboratory documentation of a 25(OH) D level at the time of hospitalization. The vitamin D levels of the patients were 27.19 ± 20.17 ng/mL. In total, 62.7% (n = 96) of the patients had a 25(OH) D level of less than 30 ng/mL and 37.25% (n = 57) had a 25(OH) D level of more than 30 ng/mL. In total, 49% (n = 75) of the patients suffered from at least one underlying disease. The univariate and multivariable regression showed that vitamin D sufficiency was not associated with a statistically significant lower risk of adverse clinical outcomes of COVID-19 such as duration of hospitalization and severity of infection (P > 0.05). CONCLUSIONS: Sufficient vitamin D levels were not found to be protective against adverse clinical outcomes in patients infected with COVID-19. Chronic disorders in COVID-19 patients were found to have greater relevance than vitamin D levels in determining the adverse outcomes of the infection. Further studies are needed to determine the role of vitamin D level in predicting the outcomes of COVID-19 infection.


Subject(s)
COVID-19/complications , Calcifediol/deficiency , Length of Stay , SARS-CoV-2/genetics , Severity of Illness Index , Vitamin D Deficiency/complications , Adult , Aged , COVID-19/epidemiology , COVID-19/virology , COVID-19 Nucleic Acid Testing , Calcifediol/blood , Cross-Sectional Studies , Female , Hospitalization , Hospitals , Humans , Iran/epidemiology , Male , Middle Aged , Retrospective Studies , Vitamin D Deficiency/blood , Vitamin D Deficiency/epidemiology
4.
J Am Assoc Nurse Pract ; 32(3): 244-251, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31232868

ABSTRACT

BACKGROUND AND PURPOSE: Type 2 diabetes and obesity are prevalent throughout the United States, and they occur at even higher rates in some southern states. This project aimed at improving outcomes for overweight/obese patients with prediabetes, thus reducing their risk of progression to type 2 diabetes. METHODS: Twenty-four adults with a diagnosis of prediabetes and body mass index ≥ 25 completed this 3-month program. The Rapid Eating Assessment for Patients (REAPs) tool was used to assess eating habits and physical activity levels. The Single-Item Literacy Screener was used to screen for limited reading ability. The following preintervention and postintervention data were obtained: weight, A1c, REAP score, and REAP Physical Activity question (REAP-PA). INTERVENTION: Monthly group educational sessions were conducted followed by individualized goal setting. The content of the sessions encompassed a lifestyle modification program based on the first five sessions of the Centers for Disease Control and Prevention "Prevent T2"curriculum, incorporating the Southern-style diet, food choices, and activity resources available in the local community. RESULTS: Results revealed a significant (p < 0.05) decrease in weight (average 4.0 ± 4.2 kg), REAP score (average 17.6 ± 16.6), and REAP-PA (average 0.6) after intervention. A1c values decreased slightly but were not statistically significant, which may be due to the limited sample size. Those with limited reading ability showed a slightly greater A1c loss than those with adequate literacy. CONCLUSIONS: A 3-month lifestyle modification program resulted in improvement in weight, eating habits, physical activity level, and A1c in overweight/obese patients at risk for type 2 diabetes.


Subject(s)
Efficiency, Organizational/standards , Prediabetic State/therapy , Risk Reduction Behavior , Adult , Body Mass Index , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/prevention & control , Diabetes Mellitus, Type 2/psychology , Efficiency, Organizational/statistics & numerical data , Female , Health Literacy , Humans , Male , Middle Aged , Prediabetic State/psychology , Program Evaluation/methods , Quality Improvement , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...